TABLE 1.
Seroreactivity in asymptomatic U.S. populationsa
| Test kit | No. of samples |
Combined |
||||||
|---|---|---|---|---|---|---|---|---|
| Nonendemic area(s) |
Endemic area(s) |
|||||||
| Pos | Equ | Neg | Pos | Equ | Neg | % reactivity | P | |
| BioPlex 2200 Lyme Total | 2 | 1 | 97 | 5 | 0 | 95 | 4.0 | Ref |
| DiaSorin LIAISON B. burgdorferi | 2 | 2 | 96 | 3 | 0 | 97 | 3.5 | 1.000 |
| Immunetics Lyme C6 | 4 | 0 | 96 | 5 | 3 | 92 | 6.0 | 0.481 |
| Zeus Borrelia VlsE1/pepC10 | 6 | 1 | 93 | 1 | 5 | 94 | 6.5 | 0.267 |
| bioMérieux VIDAS Lyme II (lgM+IgG) | 4 | 6 | 90 | 4 | 1 | 95 | 7.5 | 0.039 |
| bioMérieux VIDAS Lyme II lgM | 3 | 6 | 91 | 2 | 1 | 97 | 6.0 | 0.289 |
| bioMérieux VIDAS Lyme II lgG | 1 | NA | 99 | 2 | NA | 98 | 1.5 | 0.180 |
a
A total of 200 normal blood donor samples collected from areas of nonendemicity (Gulf Coast, n = 100) and endemicity (Northeast, n = 100) in the United States were assessed for reactivity to the listed commercially available Lyme test kits. Pos, positive; Equ, equivocal; Neg, negative; Ref, reference; NA, not applicable.